SARS-CoV-2 protease and inhibitor Nirmatrelvir

3D Model

Since the outbreak of Coronavirus disease in December 2019, the pandemic has grown to a global scale and impacted many lives. This has made it extremely important for treatments to be developed to help reduce the rates of hospitalisation and death in communities . Nirmatrelvir (PF-07321332) is one such potential treatment - an irreversible protease inhibitor. It is used as an orally administered treatment to help protect against serious COVID-19 symptoms.

SARS-CoV-2 protease is the main drug target as it is responsible for the maturation of itself and other polyproteins such as Nirmatrelvir which acts as an antiviral protease inhibitor. It is important to understand these interactions because it helps us to understand how they can work together to create a cleave between polyproteins active in coronavirus.

The sketchfab model shows the biomolecular interaction between the SARS-CoV-2 main protease and inhibitor Nirmatrelvir.